Arielle R. Nagler
Research Subjects
Arielle R. Nagler has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Amanda Bienenfeld
New York University School of Medicine, New York University School of Medicine, New York, New York
3 shared publications- Sarah Azarchi
New York University School of Medicine, New York, New York
3 shared publications Jerry Shapiro
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York
2 shared publicationsKristen Lo Sicco
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York
2 shared publications- Seth J. Orlow
Ronald O. Perelman Department of Dermatology NYU Grossman School of Medicine New York New York USA
2 shared publications Shari Marchbein
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York
2 shared publications
Latest Publications
- Open Access
- 15 October 2022
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 79 (24) , 2222-2229
The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study
In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis. A retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19–specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis. A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis.
- 15 October 2022
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 79 (24) , 2222-2229
Open AccessThe impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study
In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. Despite progress in the treatment of coronavirus disease 2019 (COVID-19), including the development of monoclonal antibodies (mAbs), more clinical data to support the use of mAbs in outpatients with COVID-19 is needed. This study is designed to determine the impact of bamlanivimab, bamlanivimab/etesevimab, or casirivimab/imdevimab on clinical outcomes within 30 days of COVID-19 diagnosis. A retrospective cohort study was conducted at a single academic medical center with 3 campuses in Manhattan, Brooklyn, and Long Island, NY. Patients 12 years of age or older who tested positive for COVID-19 or were treated with a COVID-19–specific therapy, including COVID-19 mAb therapies, at the study site between November 24, 2020, and May 15, 2021, were included. The primary outcomes included rates of emergency department (ED) visit, inpatient admission, intensive care unit (ICU) admission, or death within 30 days from the date of COVID-19 diagnosis. A total of 1,344 mAb-treated patients were propensity matched to 1,344 patients with COVID-19 patients who were not treated with mAb therapy. Within 30 days of diagnosis, among the patients who received mAb therapy, 101 (7.5%) presented to the ED and 79 (5.9%) were admitted. Among the patients who did not receive mAb therapy, 165 (12.3%) presented to the ED and 156 (11.6%) were admitted (relative risk [RR], 0.61 [95% CI, 0.50-0.75] and 0.51 [95% CI, 0.40-0.64], respectively). Four mAb patients (0.3%) and 2.64 control patients (0.2%) were admitted to the ICU (RR, 01.51; 95% CI, 0.45-5.09). Six mAb-treated patients (0.4%) and 3.37 controls (0.3%) died and/or were admitted to hospice (RR, 1.61; 95% CI, 0.54-4.83). mAb therapy in ambulatory patients with COVID-19 decreases the risk of ED presentation and hospital admission within 30 days of diagnosis.
- 1 June 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 80 (6) , 1509-1521
Androgens in women
- 1 June 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 80 (6) , 1509-1521
Androgens in women
- 1 June 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 80 (6) , 1497-1506
Androgens in women
- 1 June 2019
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 80 (6) , 1497-1506
Androgens in women
- 1 June 2018
- Vol. 17 (6) , 686-687
Currently Constrained, Dermatologists Are Ready for New Acne Therapies
Acne is the most common skin condition in the United States, affecting 50 million Americans annually. The disease's severity can range from mild to severe, with approximately 20% of people with acne experiencing moderate to severe disease.
- 1 June 2018
- Vol. 17 (6) , 686-687
Currently Constrained, Dermatologists Are Ready for New Acne Therapies
Acne is the most common skin condition in the United States, affecting 50 million Americans annually. The disease's severity can range from mild to severe, with approximately 20% of people with acne experiencing moderate to severe disease.
- 1 April 2018
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 154 (4) , 401
Lupus—Crying Wolf
Over a short period in the 18th century, in the province of Gévaudan in the French countryside, an estimated 210 people were killed in a string of unexplained wolf attacks that captured popular imagination and survived in fairytales that are still prevalent today: stories from “Little Red Riding Hood” to the various legends of werewolves are traced to this period.1 As further evidence of the hold that fear of wolves had on civilized society at the time, somewhat contemporaneously with the attacks of Gévaudan, “lupus” was widely adopted into medical nomenclature.2Lupus is Latin for wolf and appears in several dermatological diagnoses. Initially, lupus was used to describe the ulcerated lesions that resembled the aftermath of a wolf’s bite.2 An early adoption of lupus, lupus vulgaris, is accurately descriptive because this manifestation of untreated tuberculosis presents with ulcerated nodules, reminiscent of a wolf bite, on the head and neck.
- 1 April 2018
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 154 (4) , 401
Lupus—Crying Wolf
Over a short period in the 18th century, in the province of Gévaudan in the French countryside, an estimated 210 people were killed in a string of unexplained wolf attacks that captured popular imagination and survived in fairytales that are still prevalent today: stories from “Little Red Riding Hood” to the various legends of werewolves are traced to this period.1 As further evidence of the hold that fear of wolves had on civilized society at the time, somewhat contemporaneously with the attacks of Gévaudan, “lupus” was widely adopted into medical nomenclature.2Lupus is Latin for wolf and appears in several dermatological diagnoses. Initially, lupus was used to describe the ulcerated lesions that resembled the aftermath of a wolf’s bite.2 An early adoption of lupus, lupus vulgaris, is accurately descriptive because this manifestation of untreated tuberculosis presents with ulcerated nodules, reminiscent of a wolf bite, on the head and neck.
- 20 March 2018
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 19 (3) , 449-455
The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study
Little is known about how dermatologists prescribe hormonal antiandrogen acne treatment (HAAT).
- 20 March 2018
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 19 (3) , 449-455
The Use of Hormonal Antiandrogen Therapy in Female Patients with Acne: A 10-Year Retrospective Study
Little is known about how dermatologists prescribe hormonal antiandrogen acne treatment (HAAT).
- 4 August 2017
- Published by Springer Nature in Lasers in Medical Science
- Vol. 32 (7) , 1647-1658
Laser treatments of active acne
The utility of laser therapy is increasingly being recognized in the treatment of active acne vulgaris. We aimed to perform a narrative review of the medical literature on the use of laser therapy for the treatment of active acne vulgaris. We performed a PubMed literature search on September 1, 2016 using the search terms “active acne,” “acne,” “laser therapy,” and “laser surgery.” Case reports, case series, cohort, and controlled trials were included. Studies of lasers in the treatment of acne, including erbium glass, Nd:YAG, pulse dye laser (PDL), potassium titanyl phosphate (KTP) laser, and laser-based photodynamic therapy, have been published. While treatment of active acne with lasers has been successful, many studies are limited by small patient number and lack of control populations and comparison to standard therapies for active acne. Laser therapies are increasingly becoming part of or an adjunct to the medical treatment of active acne and are a useful treatment modality.
- 4 August 2017
- Published by Springer Nature in Lasers in Medical Science
- Vol. 32 (7) , 1647-1658
Laser treatments of active acne
The utility of laser therapy is increasingly being recognized in the treatment of active acne vulgaris. We aimed to perform a narrative review of the medical literature on the use of laser therapy for the treatment of active acne vulgaris. We performed a PubMed literature search on September 1, 2016 using the search terms “active acne,” “acne,” “laser therapy,” and “laser surgery.” Case reports, case series, cohort, and controlled trials were included. Studies of lasers in the treatment of acne, including erbium glass, Nd:YAG, pulse dye laser (PDL), potassium titanyl phosphate (KTP) laser, and laser-based photodynamic therapy, have been published. While treatment of active acne with lasers has been successful, many studies are limited by small patient number and lack of control populations and comparison to standard therapies for active acne. Laser therapies are increasingly becoming part of or an adjunct to the medical treatment of active acne and are a useful treatment modality.
- 1 February 2015
- Vol. 14 (2) , 184-9
Dermatologists' attitudes, prescription, and counseling patterns for isotretinoin: a questionnaire-based study.
Isotretinoin, the most effective therapy for severe acne, has engendered controversy. These controversies impact dermatologists' opinions of isotretinoin and prescription behaviors. This study was designed to characterize dermatologists' opinions of controversies surrounding isotretinoin, as well as counseling and prescribing practices. A 25-question survey was emailed to 7,013 dermatologists included in a proprietary database (MBD, Inc.) and anonymous responses were collected. 591 board-certified dermatologists participated. Thirty-seven percent of the responding dermatologists believe that isotretinoin may cause psychiatric disturbances. Dermatologists' opinions on this relationship did not significantly impact prescription practices in patients with history of depression (P=0.056) or in patients being treated with an antidepressant (P=0.118). A larger percentage of dermatologists surveyed believe there is a causal relationship between isotretinoin and psychiatric disturbances than isotretinoin and IBD. Of the surveyed dermatologists, 2.7% believe there is a causal association between isotretinoin and inflammatory bowel disease IBD. In addition, physicians with 20 or fewer years of experience, which included 50% of the responding dermatologists, were significantly less likely to have read the patient brochure (P=0.004), and more likely to prescribe isotretinoin to patients who had not failed systemic antibiotics (P=0.015). This questionnaire also may highlight a practice gap, as more recently trained dermatologists appear less likely to require failure of systemic antibiotics prior to initiating isotretinoin.
- 1 February 2015
- Vol. 14 (2) , 184-9
Dermatologists' attitudes, prescription, and counseling patterns for isotretinoin: a questionnaire-based study.
Isotretinoin, the most effective therapy for severe acne, has engendered controversy. These controversies impact dermatologists' opinions of isotretinoin and prescription behaviors. This study was designed to characterize dermatologists' opinions of controversies surrounding isotretinoin, as well as counseling and prescribing practices. A 25-question survey was emailed to 7,013 dermatologists included in a proprietary database (MBD, Inc.) and anonymous responses were collected. 591 board-certified dermatologists participated. Thirty-seven percent of the responding dermatologists believe that isotretinoin may cause psychiatric disturbances. Dermatologists' opinions on this relationship did not significantly impact prescription practices in patients with history of depression (P=0.056) or in patients being treated with an antidepressant (P=0.118). A larger percentage of dermatologists surveyed believe there is a causal relationship between isotretinoin and psychiatric disturbances than isotretinoin and IBD. Of the surveyed dermatologists, 2.7% believe there is a causal association between isotretinoin and inflammatory bowel disease IBD. In addition, physicians with 20 or fewer years of experience, which included 50% of the responding dermatologists, were significantly less likely to have read the patient brochure (P=0.004), and more likely to prescribe isotretinoin to patients who had not failed systemic antibiotics (P=0.015). This questionnaire also may highlight a practice gap, as more recently trained dermatologists appear less likely to require failure of systemic antibiotics prior to initiating isotretinoin.